Core Viewpoint - ZyVersa Therapeutics, Inc. has entered into a warrant inducement agreement with an institutional investor, which includes the immediate exercise of existing warrants and the issuance of new warrants at a reduced exercise price of $0.67, generating approximately $2.0 million in gross cash proceeds for working capital and corporate purposes [1][2]. Group 1 - The agreement involves the immediate exercise of Series A-2 Warrants for up to 957,200 shares and Series A-3 Warrants for up to 2,105,265 shares at an exercise price of $0.67 [1]. - The investor will receive new Series A-4 Warrants to purchase up to 6,124,930 shares, which will be exercisable upon stockholder approval and will expire five years from that date [2]. - The transaction is expected to close on or about July 9, 2025, pending customary closing conditions [2]. Group 2 - A.G.P./Alliance Global Partners served as the exclusive financial advisor for this transaction [3]. - The new warrants were offered in a private placement under an exemption from the registration requirements of the Securities Act, and the company plans to file a registration statement with the SEC for the resale of common stock upon exercise of the new warrants [4]. Group 3 - ZyVersa Therapeutics is a clinical stage specialty biopharmaceutical company focused on developing first-in-class drugs for renal and inflammatory diseases, utilizing proprietary technologies such as Cholesterol Efflux Mediator™ VAR 200 and Inflammasome ASC Inhibitor IC 100 [6].

Core Viewpoint - Adial Pharmaceuticals, Inc. has entered into a warrant inducement agreement with an institutional investor for the immediate exercise of existing Series B and Series C Warrants, aiming to raise approximately $2.75 million for working capital and corporate purposes [1][3]. Group 1: Warrant Inducement Agreement - The agreement involves the exercise of Series B Warrants to purchase up to 1,418,440 shares and Series C Warrants for up to 2,300,000 shares at a reduced exercise price of $0.74 [1]. - In exchange for the immediate exercise of the Existing Warrants, the investor will receive new Series B-1 and Series C-1 Warrants, allowing the purchase of up to 2,482,270 and 4,025,000 shares respectively, also at an exercise price of $0.74 [3]. - The closing of this transaction is expected around May 5, 2025, pending customary closing conditions [3]. Group 2: Use of Proceeds - The net proceeds from this offering will be utilized for working capital and other general corporate purposes [1]. Group 3: Company Overview - Adial Pharmaceuticals is focused on developing therapies for addiction and related disorders, with its lead product AD04 targeting Alcohol Use Disorder (AUD) [6]. - AD04 has shown promising results in a pivotal Phase 3 clinical trial, indicating potential effectiveness in reducing drinking among heavy drinkers with specific genetic profiles [6]. - The company also believes AD04 may be effective in treating other addictive disorders, including Opioid Use Disorder, gambling, and obesity [6].